Indian Cobra venom toxins (NNV)

Indian Cobra (Naja naja) venom toxins are a complex mixture of bioactive proteins and peptides that serve as the primary pathological agents in snakebite envenomation [5, 8]. The venom proteome is dominated by three-finger toxins (3FTxs), specifically postsynaptic alpha-neurotoxins and cytotoxins (cardiotoxins), as well as enzymatic components like phospholipase A2 (PLA2) and snake venom metalloproteinases (SVMPs) [3, 11]. Alpha-neurotoxins induce neuromuscular paralysis by competitively binding to nicotinic acetylcholine receptors (nAChRs) at the neuromuscular junction, which can lead to fatal respiratory failure [4, 13]. Cytotoxins contribute to extensive local tissue necrosis (dermonecrosis) and cardiac dysfunction by disrupting cell membrane integrity and activating apoptotic pathways [2, 3]. These toxins are the therapeutic targets for polyvalent antivenoms, which utilize equine-derived antibodies to neutralize venom components [5, 11]. Recent research also highlights the potential of small molecule inhibitors, such as Varespladib for PLA2 and heparinoids for cytotoxins, to supplement traditional antivenom therapy and mitigate local tissue damage [12].

Other names

Naja naja venom toxinsSpectacled cobra venom toxinsIndian cobra venom proteinsCobra venom toxins

Antivenoms neutralize toxins through antibody-mediated binding, preventing their interaction with physiological targets like nicotinic acetylcholine receptors [5, 11]. Small molecule inhibitors like Varespladib competitively inhibit the enzymatic activity of phospholipase A2 [12].